mst continus suspension 20 mg
mundipharma pharmaceuticals limited - morphine sulfate - prolonged-release granules for oral suspension - 20 milligram(s) - natural opium alkaloids; morphine
oxycontin 60 milligram tablet prolonged release
mundipharma pharmaceuticals limited - oxycodone hydrochloride - tablet prolonged release - 60 milligram - natural opium alkaloids
oxycontin 120 milligram tablet prolonged release
mundipharma pharmaceuticals limited - oxycodone hydrochloride - tablet prolonged release - 120 milligram - natural opium alkaloids
oxycontin 15 milligram tablet prolonged release
mundipharma pharmaceuticals limited - oxycodone hydrochloride - tablet prolonged release - 15 milligram - natural opium alkaloids
oxycontin 160 milligram tablet prolonged release
mundipharma pharmaceuticals limited - oxycodone hydrochloride - tablet prolonged release - 160 milligram - natural opium alkaloids
oxycontin 30 milligram tablet prolonged release
mundipharma pharmaceuticals limited - oxycodone hydrochloride - tablet prolonged release - 30 milligram - natural opium alkaloids
eligard leuprorelin acetate 30mg modified release injection syringe
mundipharma pty ltd - leuprorelin acetate, quantity: 30 mg - injection, modified release - excipient ingredients: n-methyl-2-pyrrolidone; polyglactin - prostate cancer,eligard 7.5mg 1 month, eligard 22.5mg 3 month, eligard 30mg 4 month and eligard 45mg 6 month are indicated for the:,? palliative treatment of advanced prostate cancer.,? treatment of high-risk localised and locally advanced hormone-dependent prostate cancer in combination with radiotherapy.
eligard leuprorelin acetate 22.5mg modified release injection syringe
mundipharma pty ltd - leuprorelin acetate, quantity: 22.5 mg - injection, modified release - excipient ingredients: n-methyl-2-pyrrolidone; polyglactin - prostate cancer,eligard 7.5mg 1 month, eligard 22.5mg 3 month, eligard 30mg 4 month and eligard 45mg 6 month are indicated for the:,? palliative treatment of advanced prostate cancer.,? treatment of high-risk localised and locally advanced hormone-dependent prostate cancer in combination with radiotherapy.
eligard leuprorelin acetate 7.5mg modified release injection syringe
mundipharma pty ltd - leuprorelin acetate, quantity: 7.5 mg - injection, modified release - excipient ingredients: n-methyl-2-pyrrolidone; polyglactin - eligard 7.5mg 1 month, eligard 22.5mg 3 month, eligard 30mg 4 month and eligard 45mg 6 month are indicated for the:,? palliative treatment of advanced prostate cancer.,? treatment of high-risk localised and locally advanced hormone-dependent prostate cancer in combination with radiotherapy.1
mundipharma burnaid burn gel
pan-malayan pharmaceuticals pte ltd - physical medicine - to cool and soothe minor burns, scalds and sunburns.